These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 24037486

  • 1. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G, Schmitz S, Broom RJ.
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B.
    Cochrane Database Syst Rev; 2020 Oct 14; 10(10):CD012796. PubMed ID: 33058158
    [Abstract] [Full Text] [Related]

  • 3. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.
    Eur Urol; 2017 Mar 14; 71(3):426-436. PubMed ID: 27939075
    [Abstract] [Full Text] [Related]

  • 4. Systemic therapy in metastatic renal cell carcinoma.
    Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K.
    World J Urol; 2017 Feb 14; 35(2):179-188. PubMed ID: 27277600
    [Abstract] [Full Text] [Related]

  • 5. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.
    Cancer Treat Rev; 2016 Nov 14; 50():109-117. PubMed ID: 27664394
    [Abstract] [Full Text] [Related]

  • 6. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H.
    Anticancer Drugs; 2016 Jun 14; 27(5):383-97. PubMed ID: 26886011
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.
    Curr Med Res Opin; 2016 Jun 14; 32(4):741-7. PubMed ID: 26744781
    [Abstract] [Full Text] [Related]

  • 8. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.
    J Med Econ; 2016 Jun 14; 19(5):462-8. PubMed ID: 26652893
    [Abstract] [Full Text] [Related]

  • 9. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
    Larkin J, Paine A, Tumur I, Cappelleri JC, Healey PJ, Foley G, Mitchell S, Kroes M, Chen C.
    Expert Opin Pharmacother; 2013 Jan 14; 14(1):27-39. PubMed ID: 23256638
    [Abstract] [Full Text] [Related]

  • 10. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A, Hamid AR, Mochtar CA, Umbas R.
    Acta Med Indones; 2016 Oct 14; 48(4):335-347. PubMed ID: 28143997
    [Abstract] [Full Text] [Related]

  • 11. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B, Rini BI, Motzer RJ, Tarazi J, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA.
    Clin Genitourin Cancer; 2015 Aug 14; 13(4):328-337.e3. PubMed ID: 25816720
    [Abstract] [Full Text] [Related]

  • 12. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI.
    Lancet Oncol; 2013 May 14; 14(6):552-62. PubMed ID: 23598172
    [Abstract] [Full Text] [Related]

  • 13. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW, Chan AL.
    Clin Ther; 2011 Jun 14; 33(6):708-16. PubMed ID: 21704235
    [Abstract] [Full Text] [Related]

  • 14. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V, Lin X, Kalanovic D, Simantov R.
    Eur Urol; 2016 Dec 14; 70(6):1006-1015. PubMed ID: 27238653
    [Abstract] [Full Text] [Related]

  • 15. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
    Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.
    Curr Med Res Opin; 2014 Apr 14; 30(4):537-45. PubMed ID: 24329572
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.
    Br J Cancer; 2014 Jun 10; 110(12):2821-8. PubMed ID: 24823696
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B.
    Cancer J; 2008 Jun 10; 14(5):325-9. PubMed ID: 18836338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.